Uromedica

Uromedica is a private, commercial-stage medical device company focused on a niche but significant urological condition: stress urinary incontinence. Its core technology, the Adjustable Continence Therapy (ACT/ProACT) system, is a minimally invasive, adjustable, and reversible implant that has been used in over 16,000 patients globally. While commercially available in Europe, Canada, and Australia, the female ACT system is still under investigation in the U.S., representing a key regulatory milestone and growth opportunity. The company operates from Plymouth, Minnesota.

Adjustable Continence Therapy (ACT): A long-term, implantable, adjustable, and reversible balloon system for treating stress urinary incontinence via periurethral compression. It features subcutaneous ports for post-operative, office-based fluid volume adjustment.

Uromedica competes in the surgical SUI device market against large medtech companies like Boston Scientific (sling systems) and Medtronic (InterStim, though for urge incontinence), as well as other sling manufacturers. Its key differentiators are the adjustability and reversibility of its balloon system, positioning it as an alternative for patients with intrinsic sphincter deficiency or those seeking a less permanent option than a sling.